U.S. OKs Lupin generic of Pfizer nerve pain drug
(Reuters) - India's Lupin Ltd said it won U.S. approval for a generic version of Pfizer Inc's big-selling Lyrica nerve pain treatment.
A spokesman for Lupin said it has not yet launched its version of Lyrica, which is also known as pregabalin.
Lyrica tallied U.S. sales of about $1.8 billion for the year ended in March, Lupin said, citing data from IMS Health Inc.
(Reporting by Lewis Krauskopf; Editing by Gerald E. McCormick)
- Target holiday cyber breach hits 40 million payment cards
- UPDATE 3-Saab wins Brazil jet deal after NSA spying sours Boeing bid
- Zuckerberg to sell Facebook shares worth about $2.3 billion
- Home sales tumble, jobless claims at near nine-month high
- Special Report: Why Ukraine spurned the EU and embraced Russia